CX3CL1 and autoimmune disease: Additionally, considering that blocking CX3CL1 has shown efficacy in reducing inflammation in autoimmune disorders and potential for treating RA, it is plausible that targeting CX3CL1 could also have beneficial effects in managing MPA/GPA55.